Research and Markets: Generalized Seizures-Pipeline Insights - Complete Pipeline Intelligence and Complete Understanding over Therapeutics Development for Generalized Seizures

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/dkd4dc/generalized) has announced the addition of the "Generalized Seizures-Pipeline Insights" report to their offering.

Generalized Seizures- Pipeline Insights provides the in-depth analysis of the pipeline assets across the Generalized Seizures. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Generalized Seizures Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

Generalized Seizures- Pipeline Insights Report covers the Generalized Seizures pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Generalized Seizures related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Generalized Seizures.

- The report provides a Generalized Seizures Landscape across the globe

- The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information

- The report reviews key players involved in the therapeutics development for Generalized Seizures and also provide company profiling

Key Topics Covered:

  • Generalized Seizures Overview
  • Generalized Seizures Pipeline Therapeutics
  • Generalized Seizures Therapeutics under Development by Companies
  • Generalized Seizures Late Stage Products (Filed and Phase III)
  • Comparative Analysis
  • Generalized Seizures Mid Clinical Stage Products (Phase II)
  • Comparative Analysis
  • Generalized Seizures Early Clinical Stage Products (Phase I and IND Filed)
  • Comparative Analysis
  • Generalized Seizures Discovery and Pre-Clinical Stage Products
  • Comparative Analysis
  • Drug Candidate Profiles
  • Generalized Seizures - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Generalized Seizures - Discontinued Products
  • Generalized Seizures - Dormant Products
  • Companies Involved in Therapeutics Development for Generalized Seizures

For more information visit http://www.researchandmarkets.com/research/dkd4dc/generalized

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals